CO-WESTERN-UNION
Western Union today announced its response to support the people and communities affected by the devastating earthquake that hit the Al-Haouz region of Morocco on Friday, 8 September.
Zero Transfer Fees1
Western Union is offering zero-fee money transfers to consumers around the world who need to send money to Morocco to support their loved ones.
- Available for payouts in cash at Agent locations2 until midnight, 12AM Central European Summer Time (CEST), on 19 September 2023.
- Available for payout into bank accounts until midnight, 12AM Central European Summer Time (CEST), on 11 October 2023.
Zero transfer fees to Morocco applies to money sent from Western Union services across its global network though all available digital channels and retail locations.
“We are deeply saddened by the tragic consequences of the earthquake that devastated the Al-Haouz region and surrounding areas of Morocco on Friday,” said Mohamed Touhami el Ouazzani, Head of Africa at Western Union. “As the country comes together in rescue efforts and the rebuild process begins, we hope that enabling zero transfers fees for consumers sending money home to their loved ones can help contribute and support. Western Union stands in solidarity with the people of Morocco. Our thoughts are with everyone that has been impacted”.
About Western Union
The Western Union Company (NYSE: WU) is committed to helping people around the world who aspire to build financial futures for themselves, their loved ones and their communities. Our leading cross-border, cross-currency money movement, payments and digital financial services empower consumers, businesses, financial institutions and governments—across more than 200 countries and territories and nearly 130 currencies—to connect with billions of bank accounts, millions of digital wallets and cards, and a global footprint of hundreds of thousands of retail locations. Our goal is to offer accessible financial services that help people and communities prosper. For more information, visit www.westernunion.com.
1 Western Union also makes money from currency exchange.
2 Due to the severity of the earthquake, some agent locations in impacted areas may not be immediately operational or possess sufficient funds. To contact your nearest Western Union agent, please click here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913940441/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Expands its Natural Ingredients Portfolio with the Launch of Coloring Foodstuffs and Natural Colors Product Lines, Enhancing Innovation in Upcycled Products16.7.2025 12:18:00 CEST | Press release
Prodalim, a global leader in juice solutions and specialty ingredients, announces the launch of its Coloring Foodstuffs and Natural Colores portfolio, marking a milestone in its commitment to delivering clean-label, plant-based, upcycled product innovations for the food and beverage industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716821011/en/ These natural color solutions are designed for seamless integration into a wide range of applications, including beverages, dairy, plant-based products, bakery, and confectionery. They offer vibrant visual appeal without compromising on performance, health standards, regulatory compliance, or consumer trust. Developed based on strict quality standards, Prodalim’s Coloring portfolio delivers optimal light resistance, pH stability, and thermal performance, addressing real-world formulation challenges while enhancing naturality, clean label credentials, and full “tree-to-table
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom